Added to YB: 2024-03-27
Pitch date: 2024-03-02
RAPT [bullish]
RAPT Therapeutics, Inc.
-48.78%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
Market Cap
$158.4M
Pitch Price
$71.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.59
P/E
-0.43
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
TimesSquare U.S. Small Cap Growth Strategy New Portfolio Holding: RAPT Therapeutics, Inc.
RAPT: Biotech developing oral therapy for eczema. Lead drug Zelnecirnon in late trials, data mid-2024. Differentiated vs injectables. Promising early results. Stock +51% since initial buy in Q1.
Read full article (1 min)